Dr Bernard Fox speaks to ecancer about the development of an anti-coronavirus vaccine using cancer research strategies.
He explains that the product, developed by OncoSec, wasn't initially designed as a vaccine but was intended to augment the immune response at the tumour site in cancer patients.
Dr Fox explains that his academic lab at the Earle A. Chiles Research Institute (Providence Cancer Institute) had been collaborating with OncoSec to study this treatment before now moving on to continue development to aid the medical need of COVID-19.
He explains how the treatment has been repurposed and also the methodology of the project testing the vaccine in individuals.
Dr Fox goes on to detail the timeline of the development of the vaccine and is hopeful that they will be able to start vaccinating people in May.